Rudolf Knauthe

Title: Rudolf Knauthe: Innovator in Pharmaceutical Composition

Introduction

Rudolf Knauthe is a notable inventor based in Glienicke, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of uterine fibroids. His innovative work has led to the development of a specific regimen for administering a progesterone receptor antagonist.

Latest Patents

Knauthe holds a patent for a selective progesterone receptor modulator (SPRM) regimen. This invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist, specifically (11β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one. The composition is intended for the treatment and/or prophylaxis of uterine fibroids, also known as myomas or uterine leiomyoma. The patent outlines a method for treating uterine fibroids and reducing their size and symptoms, as well as addressing heavy menstrual bleeding (HMB).

Career Highlights

Throughout his career, Knauthe has worked with prominent companies in the pharmaceutical industry. He has been associated with Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH. His work in these organizations has contributed to advancements in medical treatments and pharmaceutical innovations.

Collaborations

Knauthe has collaborated with notable colleagues, including Christian Seitz and Susan Zeun. These partnerships have fostered a collaborative environment that encourages innovation and the development of effective pharmaceutical solutions.

Conclusion

Rudolf Knauthe's contributions to the field of pharmaceuticals, particularly through his patent for a selective progesterone receptor modulator regimen, highlight his role as an innovator. His work continues to impact the treatment of uterine fibroids and improve patient outcomes.